On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened lower -5.23% from the last session, before settling in for the closing price of $7.26. Price fluctuations for RXRX have ranged from $5.60 to $15.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 132.77% over the past five years. Company’s average yearly earnings per share was noted 2.85% at the time writing. With a float of $323.50 million, this company’s outstanding shares have now reached $390.76 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 17.21%, while institutional ownership is 57.88%. The most recent insider transaction that took place on Jan 10 ’25, was worth 141,000. Before that another transaction happened on Jan 08 ’25, when Company’s Officer proposed sale 20,000 for $7.31, making the entire transaction worth $146,200.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 2.85% per share during the next fiscal year.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 16.8 million, a positive change from its year-to-date volume of 16.75 million. As of the previous 9 days, the stock’s Stochastic %D was 24.05%. Additionally, its Average True Range was 0.68.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 32.41%, which indicates a significant decrease from 34.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.70% in the past 14 days, which was higher than the 87.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.91, while its 200-day Moving Average is $7.57. Nevertheless, the first resistance level for the watch stands at $7.04 in the near term. At $7.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.34. If the price goes on to break the first support level at $6.75, it is likely to go to the next support level at $6.62. The third support level lies at $6.45 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 390,722K shares outstanding in the company with a market cap of 2.69 billion. Presently, the company’s annual sales total 44,580 K according to its annual income of -328,070 K. Last quarter, the company’s sales amounted to 26,080 K and its income totaled -95,840 K.
